Description: Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular products worldwide. Its products include the Neovasc Reducer for the treatment of refractory angina; and Tiara technology in development for the transcatheter treatment of mitral valve disease. The company also develops and manufactures the PeriPatch, a line of biological tissue products for use in third-party medical products, including transcatheter heart valves. In addition, the company provides a range of custom Peripatch products to industry customers for incorporation into their own products; and consulting and original equipment manufacturing services to other medical device companies. Further, it offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Home Page: www.neovasc.com
NVCN Technical Analysis
13562 Maycrest Way
Richmond,
BC
V6V 2J7
Canada
Phone:
604 270 4344
Officers
| Name | Title |
|---|---|
| Mr. Fredericus A. Colen | Pres, CEO & Director |
| Mr. Christopher Clark B.A., BA (Honours), C.A., CA, PgD | CFO & Corp. Sec. |
| Mr. William Reed Little | Chief Operating Officer |
| Mr. John Christopher Panton | Chief Quality Officer |
| Sarah Marie-Hodgson Gallagher | VP of Clinical Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9983 |
| Price-to-Sales TTM: | 9.3708 |
| IPO Date: | 2007-02-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 49 |